TREANDA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TREANDA (TREANDA).
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
| Metabolism | Primarily metabolized by hydrolysis to monohydroxy and dihydroxy metabolites. Minor metabolism via CYP1A2 to active metabolite gamma-hydroxybendamustine (M3) and N-desmethylbendamustine (M4). |
| Excretion | Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies). |
| Half-life | Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation. |
| Protein binding | 94-96% bound, primarily to serum albumin and to a lesser extent alpha-1-acid glycoprotein. |
| Volume of Distribution | Vdss: ~25-50 L (approx. 0.3-0.7 L/kg). Large Vd indicates extensive tissue distribution; accumulation in tumors via passive diffusion. |
| Bioavailability | Only intravenous administration; oral bioavailability not applicable (not orally administered). |
| Onset of Action | IV administration: Clinical effect onset within days to weeks; cytotoxicity occurs rapidly after reconstitution and infusion, but therapeutic response in CLL or NHL typically seen after 1-2 cycles. |
| Duration of Action | Duration of pharmacodynamic effect (DNA damage repair): ~24-48 hours per dose. Clinical cycles typically 28 days; maximal myelosuppression occurs 15-21 days post-infusion. |
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
| Dosage form | INJECTABLE |
| Renal impairment | For CrCl < 40 mL/min, reduce dose to 100 mg/m2 on Days 1 and 2 of a 21-day cycle. |
| Liver impairment | For Child-Pugh Class B: reduce dose to 100 mg/m2 on Days 1 and 2 of a 21-day cycle. Child-Pugh Class C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients; no standard dosing. |
| Geriatric use | No specific dose adjustment; monitor renal function and hematologic parameters closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TREANDA (TREANDA).
| Breastfeeding | No data on presence in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in nursing infants (e.g., myelosuppression, carcinogenesis), breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. |
| Teratogenic Risk | First trimester: Bendamustine is embryotoxic and teratogenic based on animal studies, causing fetal malformations and death; avoid use. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and neonatal myelosuppression; use only if maternal benefit outweighs risk. |
■ FDA Black Box Warning
Black Box Warning: TREANDA causes myelosuppression, including severe neutropenia and thrombocytopenia, which can lead to serious or fatal infections and bleeding. It also has a risk of infusion-related reactions and may cause severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Use in pregnant women can cause fetal harm.
| Serious Effects |
["Hypersensitivity to bendamustine or any component of the formulation","Concurrent administration with yellow fever vaccine or other live vaccines"]
| Precautions | ["Myelosuppression: Monitor blood counts; dose delay or reduction required for severe cytopenias","Infusion reactions: Premedicate with antihistamines, antipyretics, and corticosteroids for Grade ≥2 reactions","Infections: Increased risk of severe infections including Pneumocystis jirovecii pneumonia and herpes virus reactivation; consider prophylaxis","Skin reactions: Discontinue if severe or progressive skin reaction occurs","Hepatotoxicity: Monitor liver function; dose reduction or discontinuation if significant elevation","Tumor lysis syndrome: Risk in CLL patients with high tumor burden; maintain hydration and consider allopurinol","Extravasation: Ensure proper IV administration; avoid infiltration","Immunization: Avoid live vaccines during and after treatment","Renal toxicity: Increased toxicity in severe renal impairment (CrCl <30 mL/min); dose reduction recommended","Embryofetal toxicity: Advise women of reproductive potential to use effective contraception"] |
Loading safety data…
| Fetal Monitoring |
| Monitor complete blood counts (CBC) weekly during pregnancy. Assess fetal growth and amniotic fluid volume via ultrasound every 4–6 weeks from second trimester. Monitor for signs of preterm labor. Assess neonatal hematologic status at birth. |
| Fertility Effects | Bendamustine may impair fertility in both males and females based on animal studies; in humans, nonclinical data suggest potential for reduced spermatogenesis and ovarian failure. Effects may be irreversible. |